Name
PANEL DISCUSSION: Contraception Panel
Date & Time
Tuesday, September 15, 2020, 12:05 PM - 12:50 PM
Speakers
Stasia Obremskey - RH Capital
Nelson Ambrogio - Bayer U.S. Pharmaceuticals
Stephen Gerrard - The Bill & Melinda Gates Foundation
Amy Welsh - Agile Therapeutics
Daniel Johnston - Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Nelson Ambrogio - Bayer U.S. Pharmaceuticals
Stephen Gerrard - The Bill & Melinda Gates Foundation
Amy Welsh - Agile Therapeutics
Daniel Johnston - Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Description
- What does the pipeline for novel contraception (female controlled, hormone free) look like today?
- How to move through the FDA space efficiently and cost effectively
- What are the market opportunities for domestic and international companies?
- Reasons for slow uptake and translation of research into practice
- How can the field be de-risked for investors to start investing?
- What needs to be demonstrated for the funds to start to flow into contraception innovation
- External innovation strategies for strategic pharmaceutical brands
- How women’s reproductive health may be shifting in terms of looking at all types of women (obesity, ethnicity etc)?
- Digital contraception support –HCPs and payors views
Session Type
Panel
Virtual Session Link